JLE

Epileptic Disorders

MENU

Post-modern therapeutic approaches for progressive myoclonus epilepsy Volume 18, supplément 2, September 2016

  • [Auger et al., 2015] Auger A., Park M., Nitschke F. Efficient delivery of structurally diverse protein cargo into mammalian cells by a bacterial toxin. Mol Pharm. 2015;12:2962-29671.
  • [Faravelli et al., 2015] Faravelli I., Nizzardo M., Comi G.P., Corti S. Spinal muscular atrophy-recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11:351-359.
  • [Iyer et al., 2015] Iyer V., Shen B., Zhang W. Off-target mutations are rare in Cas9-modified mice. Nat Methods. 2015;12:479.
  • [Keiser et al., 2015] Keiser M.S., Kordasiewicz H.B., McBride J.L. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet. 2015;25:R53-64.
  • [Maegawa et al., 2007] Maegawa G.H., Tropak M., Buttner J. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem. 2007;282:9150-9161.
  • [Meyer et al., 2015] Meyer K., Ferraiuolo L., Schmelzer L. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and non-human primates. Mol Ther. 2015;23:477-487.
  • [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord. 2016;18:S1-S158. Suppl. 2
  • [Osher et al., 2015] Osher E., Fattal-Valevski A., Sagie L. Effect of cyclic, low dose pyrimethamine treatment in patients with late onset Tay Sachs: an open label, extended pilot study. Orphanet J Rare Dis. 2015;10:45.
  • [Phillips et al., 2015] Phillips M.I., Costales J., Lee R.J., Oliveira E., Burns A.B. Antisense therapy for cardiovascular diseases. Curr Pharm Des. 2015;21:4417-4426.
  • [Ran et al., 2015] Ran F.A., Cong L., Yan W.X. genome editing using Cas9. Nature. 2015;520:186-191. In vivoStaphylococcus aureus
  • [Ricos et al., 2015] Ricos M.G., Hodgson B.L., Pippucci T. Mutations in the mTOR pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol. 2015;79:120-131.
  • [Turnbull et al., 2016] Turnbull J, Striano P, Genton P, Carpenter S, Ackerley CA, Minassian BA. Lafora Disease. Epileptic Disord 2016; 18(Suppl.2) : S38-62.
  • [Zetsche et al., 2015] Zetsche B., Gootenberg J.S., Abudayyeh O.O. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759-771.